NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that it will present three abstracts at the EASL 2016 annual meeting to be held April 13-26, 2017 in Barcelona, Spain.
These presentations will disclose updated clinical, pre-clinical and mechanistic data on the activity of NAPs against chronic hepatitis B and hepatitis D infection:
These presentations will disclose updated clinical, pre-clinical and mechanistic data on the activity of NAPs against chronic hepatitis B and hepatitis D infection:
